AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27906919 — intervention group
Group type: COMPARATOR
Intervention: Percussion test (first 25 subjects)
Number of subjects: 50
Study 27906919 — intervention group
Group type: EXPERIMENTAL
Intervention: Scratch test (first 25 subjects)
Number of subjects: 50
Study 24569001 — intervention group
Group type: EXPERIMENTAL
Intervention: Employer-provided insurance
Number of subjects: 5755
Study 24569001 — intervention group
Group type: EXPERIMENTAL
Intervention: Spousal insurance
Number of subjects: 5755
Study 24569001 — intervention group
Group type: EXPERIMENTAL
Intervention: Market insurance
Number of subjects: 5755
Study 24569001 — intervention group
Group type: COMPARATOR
Intervention: Baseline models (no specific intervention)
Number of subjects: 5755
Study 23258136 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol hydrochloride (10 µg/kg/min, continuous intravenous)
Number of subjects: 60
Study 23258136 — intervention group
Group type: COMPARATOR
Intervention: Control (no landiolol)
Number of subjects: 60
Study 23258136 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol hydrochloride
Number of subjects: 60
Study 21085712 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect comparisons using randomised controlled trials
Number of subjects: 43
Study 18501909 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg intravenous dose
Number of subjects: 43
Study 15987918 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral capecitabine (1004 patients)
Number of subjects: 1987
Study 15987918 — intervention group
Group type: COMPARATOR
Intervention: Bolus fluorouracil plus leucovorin (983 patients)
Number of subjects: 1987
Study 14525817 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 60 mg
Number of subjects: 15
Study 14525817 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 0.03 mg/kg prior to ropivacaine
Number of subjects: 15
Study 14525817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 11027451 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 11
Study 8808721 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide 5 g/m2xdx1 and doxorubicin 60 mg/m2xdx1 given every 3 weeks with r‐met Hu G‐CSF (250 micrograms/m2xd)
Number of subjects: 60
Study 8808721 — intervention group
Group type: COMPARATOR
Intervention: Ifosfamide 1.8 g/m2xdx5 and doxorubicin 60 mg/m2xdx1 given every 4 weeks
Number of subjects: 60
Study 1419009 — intervention group
Group type: EXPERIMENTAL
Intervention: IM ketorolac 30 mg while in the PACU, followed by 15 mg every 6 hours
Number of subjects: 35
Study 1419009 — intervention group
Group type: EXPERIMENTAL
Intervention: IM ketorolac 60 mg while in the PACU, followed by 30 mg every 6 hours
Number of subjects: 35
Study 1419009 — intervention group
Group type: COMPARATOR
Intervention: IV PCA morphine
Number of subjects: 35
Study 1419009 — intervention group
Group type: COMPARATOR
Intervention: IM saline every 6 hours
Number of subjects: 35
Study 6198912 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal male expectancy condition
Number of subjects: 40
Study 6198912 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal female expectancy condition
Number of subjects: 40
Study 6198912 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmentally delayed male expectancy condition
Number of subjects: 40
Study 6198912 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmentally delayed female expectancy condition
Number of subjects: 40
Study 6198912 — intervention group
Group type: EXPERIMENTAL
Intervention: Label 'developmentally delayed'
Number of subjects: 40
Study 6198912 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal prompts
Number of subjects: 40
Study 30721941 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based micronutrient supplement commenced ≥3 months before conception (Arm 1)
Number of subjects: 7387
Study 30721941 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based micronutrient supplement commenced late in the first trimester of pregnancy (Arm 2)
Number of subjects: 7387
Study 30721941 — intervention group
Group type: COMPARATOR
Intervention: Control group (Arm 3)
Number of subjects: 7387
Study 28668540 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 103
Study 28668540 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 103
Study 28668540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 27113302 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution-focused approach
Number of subjects: 120
Study 27113302 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing and psychological guidance
Number of subjects: 120
Study 25136038 — intervention group
Group type: EXPERIMENTAL
Intervention: VIS and information emphasizing the MMR vaccine's benefits to the child
Number of subjects: 802
Study 25136038 — intervention group
Group type: EXPERIMENTAL
Intervention: VIS and information emphasizing benefits both to the child and society
Number of subjects: 802
Study 25136038 — intervention group
Group type: COMPARATOR
Intervention: VIS only
Number of subjects: 802
Study 25136038 — intervention group
Group type: EXPERIMENTAL
Intervention: VIS and information emphasizing societal benefits
Number of subjects: 802
Study 22190555 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam (0.30 mg/kg)
Number of subjects: 81
Study 22190555 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam (0.05 to 0.20 mg/kg)
Number of subjects: 81
Study 22190555 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.075 mg/kg)
Number of subjects: 81
Study 22190555 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam (0.10 and 0.15 mg/kg)
Number of subjects: 81
Study 22190555 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam and Midazolam
Number of subjects: 81
Study 20107469 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 202
Study 17287638 — intervention group
Group type: EXPERIMENTAL
Intervention: Batroxobin
Number of subjects: 112
Study 17287638 — intervention group
Group type: COMPARATOR
Intervention: Control (no batroxobin)
Number of subjects: 112
Study 11160991 — intervention group
Group type: EXPERIMENTAL
Intervention: Government intervention strategies implemented in the tuna farming industry.
Number of subjects: 17
Study 9311393 — intervention group
Group type: COMPARATOR
Intervention: Thiopental 5 mg kg‐1 induction and isoflurane maintenance (Group T/I)
Number of subjects: 90
Study 9311393 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2 mg kg‐1 induction, 5 mg kg‐1 h‐1 maintenance (Group P5)
Number of subjects: 90
Study 9311393 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2 mg kg‐1 induction, 10 mg kg‐1 h‐1 maintenance (Group P10)
Number of subjects: 90
Study 8354977 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 28
Study 8354977 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 28
Study 3088859 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil 35 micrograms b.i.d.
Number of subjects: 93
Study 3088859 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg b.i.d.
Number of subjects: 93
Study 30468145 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (15 mg daily for 2 weeks, then 30 mg daily for up to 12 months)
Number of subjects: 480
Study 30468145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study 30468145 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 480
Study 27340354 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant sorafenib
Number of subjects: 34
Study 27340354 — intervention group
Group type: COMPARATOR
Intervention: Control group (curative hepatectomy without sorafenib)
Number of subjects: 34
Study 25172798 — intervention group
Group type: EXPERIMENTAL
Intervention: Korodin(®) (20 drops administered four times with 10 min intervals)
Number of subjects: 54
Study 25172798 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 drops administered four times with 10 min intervals)
Number of subjects: 54
Study 25172798 — intervention group
Group type: EXPERIMENTAL
Intervention: Korodin(®)
Number of subjects: 54
Study 25172798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 22415678 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg
Number of subjects: 60
Study 22415678 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 60
Study 19944431 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 21
Study 18450618 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly cross-linked polyethylene
Number of subjects: 54
Study 18450618 — intervention group
Group type: COMPARATOR
Intervention: Standard polyethylene
Number of subjects: 54
Study 15812079 — intervention group
Group type: EXPERIMENTAL
Intervention: Menopausal hormone therapy
Number of subjects: 378
Study 15812079 — intervention group
Group type: COMPARATOR
Intervention: No menopausal hormone therapy
Number of subjects: 378
Study 14516801 — intervention group
Group type: EXPERIMENTAL
Intervention: Patching treatment (6 hours per day up to all waking hours)
Number of subjects: 209
Study 10795832 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate
Number of subjects: 189
Study 10795832 — intervention group
Group type: COMPARATOR
Intervention: Iobitridol
Number of subjects: 189
Study 9679606 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 0
Study 9679606 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 0
Study 9679606 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 0
Study 9679606 — intervention group
Group type: COMPARATOR
Intervention: H2-receptor antagonists and proton pump inhibitors
Number of subjects: 0
Study 9679606 — intervention group
Group type: COMPARATOR
Intervention: Drugs for erosions
Number of subjects: 0
Study 1500398 — intervention group
Group type: EXPERIMENTAL
Intervention: Flosequinan 50 mg daily for 4 weeks
Number of subjects: 24
Study 1500398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30383333 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 482
Study 30383333 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine
Number of subjects: 482
Study 30383333 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium or Quetiapine
Number of subjects: 482
Study 28395435 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia combined with epidural anesthesia and epidural analgesia (GE)
Number of subjects: 96
Study 28395435 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia and intravenous analgesia (GI)
Number of subjects: 96
Study 26547293 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 60
Study 26547293 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil plus flurbiprofen axetil
Number of subjects: 60
Study 23003913 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediately Loaded (IL) DLMF transitional implants
Number of subjects: 12
Study 23003913 — intervention group
Group type: COMPARATOR
Intervention: Unloaded (UI) DLMF transitional implants
Number of subjects: 12
Study 22225438 — intervention group
Group type: EXPERIMENTAL
Intervention: Written feedback from standardized patients
Number of subjects: 0
Study 22225438 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of written and verbal feedback from standardized patients
Number of subjects: 0
Study 22225438 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 0
Study 22225438 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention groups (written and verbal feedback)
Number of subjects: 0
Study 19923803 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan
Number of subjects: 416
Study 19923803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study 18555088 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate-sodium (EC-MPS) 720 mg b.i.d
Number of subjects: 154
Study 18555088 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) 1000 mg b.i.d
Number of subjects: 154
Study 16018522 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dimethylsulfoxide (DMSO)
Number of subjects: 66
Study 16018522 — intervention group
Group type: COMPARATOR
Intervention: Topical saline (Control)
Number of subjects: 66
Study 12185791 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective reports of exposure during pregnancy
Number of subjects: 29
Study 12185791 — intervention group
Group type: COMPARATOR
Intervention: Retrospective reports of exposure 3-7 years after pregnancy
Number of subjects: 29
Study 10522577 — intervention group
Group type: EXPERIMENTAL
Intervention: Thigh tourniquet inflated during surgery (Group I)
Number of subjects: 30
Study 10522577 — intervention group
Group type: COMPARATOR
Intervention: No thigh tourniquet inflated during surgery (Group II)
Number of subjects: 30
Study 7856780 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention (18-month multifaceted program with employee steering committee and tailored activities)
Number of subjects: 26
Study 7856780 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (control group)
Number of subjects: 26
Study 1835851 — intervention group
Group type: EXPERIMENTAL
Intervention: iproplatin
Number of subjects: 47
Study 1835851 — intervention group
Group type: COMPARATOR
Intervention: carboplatin
Number of subjects: 47
Study 6120980 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 or 112 microgram of a pili vaccine prepared from Neisseria gonorrhoeae strain F62 in Tris buffer with an aluminum phosphate adjuvant (alum)
Number of subjects: 39
Study 6120980 — intervention group
Group type: EXPERIMENTAL
Intervention: 220 microgram of the F62 pili vaccine prepared in ethanolamine, with or without alum
Number of subjects: 39
Study 6120980 — intervention group
Group type: EXPERIMENTAL
Intervention: Postimmunization sera
Number of subjects: 39
Study 6120980 — intervention group
Group type: EXPERIMENTAL
Intervention: Preabsorption of the sera with strain F62 pili
Number of subjects: 39
Study 30957833 — intervention group
Group type: EXPERIMENTAL
Intervention: MIX (1:1 blend of sodium selenite and SEL-PLEX)
Number of subjects: 24
Study 30957833 — intervention group
Group type: EXPERIMENTAL
Intervention: OSe (SEL-PLEX)
Number of subjects: 24
Study 30957833 — intervention group
Group type: COMPARATOR
Intervention: ISe (sodium selenite)
Number of subjects: 24
Study 28745912 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological grief counseling (4 sessions over 2 weeks)
Number of subjects: 100
Study 28745912 — intervention group
Group type: COMPARATOR
Intervention: Routine postnatal care (control group)
Number of subjects: 100
Study 25913893 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride rinse (sodium fluoride and amine fluoride), used every evening after toothbrushing
Number of subjects: 81
Study 25913893 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse, used every evening after toothbrushing
Number of subjects: 81
Study 25913893 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 81
Study 25913893 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride rinse
Number of subjects: 81
Study 23876588 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily
Number of subjects: 1500
Study 23876588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1500
Study 22428487 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 1.5 mg ml(-1) plus fentanyl 2 microg ml(-1) (group F)
Number of subjects: 52
Study 22428487 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 1.5 mg ml(-1) plus clonidine 1 microg ml(-1) (group C)
Number of subjects: 52
Study 18533158 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80mg
Number of subjects: 19
Study 18533158 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin/ezetimibe 10mg/10mg
Number of subjects: 19
Study 18533158 — intervention group
Group type: COMPARATOR
Intervention: Fat loading without treatment
Number of subjects: 19
Study 17874823 — intervention group
Group type: EXPERIMENTAL
Intervention: P40 tablets (2250 mg/d, 900 mg/d of CoQ10) for 4 weeks
Number of subjects: 46
Study 17874823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 15541675 — intervention group
Group type: EXPERIMENTAL
Intervention: ProDisc II
Number of subjects: 78
Study 15541675 — intervention group
Group type: COMPARATOR
Intervention: 360-degree lumbar spinal fusion
Number of subjects: 78
Study 11277606 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/70 kg triazolam, ingested orally 30 min before bedtime
Number of subjects: 11
Study 11277606 — intervention group
Group type: COMPARATOR
Intervention: Placebo, ingested orally 30 min before bedtime
Number of subjects: 11
Study 11277606 — intervention group
Group type: COMPARATOR
Intervention: Random choice between triazolam and placebo
Number of subjects: 11
Study 11277606 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-sleep questionnaires
Number of subjects: 11
Study 9775243 — intervention group
Group type: EXPERIMENTAL
Intervention: Syringing with retropunctal cautery (RPC) and one-snip punctoplasty (group B)
Number of subjects: 30
Study 9775243 — intervention group
Group type: COMPARATOR
Intervention: Syringing alone (group A)
Number of subjects: 30
Study 7843192 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms EE/day (n = 11)
Number of subjects: 52
Study 7843192 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 micrograms EE/day (n = 25)
Number of subjects: 52
Study 7843192 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms EE/day (n = 16)
Number of subjects: 52
Study 7843192 — intervention group
Group type: COMPARATOR
Intervention: Untreated group A (n = 21)
Number of subjects: 52
Study 3339140 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg acyclovir twice a day
Number of subjects: 0
Study 3339140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3339140 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg acyclovir five times a day for 5 days, then 400 mg three times a day for 1 or 2 months, followed by 400 mg twice a day thereafter
Number of subjects: 0
Study 3339140 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg oral acyclovir five or six times a day for 5 to 10 days
Number of subjects: 0
Study 29294497 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction drainage (CSD)
Number of subjects: 36
Study 29294497 — intervention group
Group type: COMPARATOR
Intervention: No closed suction drainage (nondrainage)
Number of subjects: 36
Study 27311484 — intervention group
Group type: EXPERIMENTAL
Intervention: Ectopic expression of K+CN11 in HEK+293T cells
Number of subjects: 0
Study 27311484 — intervention group
Group type: EXPERIMENTAL
Intervention: Disruption of the K+CN11 gene or mutation of key residues for K++ permeability
Number of subjects: 0
Study 27311484 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutant cells with disrupted K+CN11
Number of subjects: 0
Study 25640151 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT), n = 76
Number of subjects: 182
Study 25640151 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT), n = 75
Number of subjects: 182
Study 25640151 — intervention group
Group type: COMPARATOR
Intervention: Waiting List Control (WLC), n = 31
Number of subjects: 182
Study 23266840 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg/day
Number of subjects: 2118
Study 23266840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2118
Study 21917633 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemia in type 2 diabetic subjects
Number of subjects: 0
Study 21917633 — intervention group
Group type: COMPARATOR
Intervention: Hyperglycemia in controls
Number of subjects: 0
Study 17524398 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: M199 + 20% fetal bovine serum (FBS) + 75 mIU/mL recombinant follicle‐stimulating hormone (FSH) + 0.5 IU/mL recombinant hCG
Number of subjects: 62
Study 17524398 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: hCG-free IVM medium (M199 + 20% FBS + 75 mIU/mL recombinant FSH) for 10 hours, then transferred to Group A medium
Number of subjects: 62
Study 17524398 — intervention group
Group type: COMPARATOR
Intervention: Group C: hCG-free IVM medium only
Number of subjects: 62
Study 15842516 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart (IAsp) injected immediately before a meal (0.15 U/kg)
Number of subjects: 37
Study 15842516 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin (HI) injected 30 min before a meal (0.15 U/kg)
Number of subjects: 37
Study 15842516 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart (IAsp)
Number of subjects: 37
Study 15842516 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin (HI)
Number of subjects: 37
Study 12204014 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (2 to 8 mg/d)
Number of subjects: 24317
Study 12204014 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone (12.5 to 25 mg/d)
Number of subjects: 24317
Study 12204014 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (after adjustment for follow-up systolic/diastolic blood pressure)
Number of subjects: 24317
Study 10328637 — intervention group
Group type: EXPERIMENTAL
Intervention: Reiki plus Reiki
Number of subjects: 20
Study 10328637 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus placebo
Number of subjects: 20
Study 10328637 — intervention group
Group type: EXPERIMENTAL
Intervention: Reiki plus placebo
Number of subjects: 20
Study 10328637 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Reiki
Number of subjects: 20
Study 7481082 — intervention group
Group type: EXPERIMENTAL
Intervention: Full vision condition
Number of subjects: 26
Study 7481082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient vision condition
Number of subjects: 26
Study 7481082 — intervention group
Group type: EXPERIMENTAL
Intervention: No vision condition
Number of subjects: 26
Study 7481082 — intervention group
Group type: COMPARATOR
Intervention: Skilled lifters across all vision conditions
Number of subjects: 26
Study 1946267 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 30
Study 1946267 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 30